Daily English Article — April 27, 2026

A Chicago police officer was killed and a second was critically wounded after a prisoner opened fire inside Swedish Hospital in the city's Lincoln Square neighborhood on Saturday morning. The incident occurred at approximately 10:50 a.m. local time. Chicago Police Superintendent Larry Snelling confirmed the details at a press conference, identifying the deceased as a 38-year-old officer with ten years of service, and the critically injured officer as a 57-year-old veteran with 21 years on the force.

The suspect, who had originally been arrested on suspicion of robbery, had been transported to the hospital for medical observation when he somehow obtained a firearm and shot both officers. After the attack, he fled the hospital and took refuge in a nearby home several blocks away. Law enforcement sources told CBS News Chicago that a third gun was also recovered during the suspect's subsequent arrest, though details about how he initially obtained the weapon were not immediately disclosed.

SWAT teams quickly surrounded the home where the suspect had barricaded himself and eventually took him into custody without further incident. Chicago Alderperson Andre Vasquez urged residents in the area to shelter in place during the standoff, warning people to steer clear of the neighborhood. Endeavor Health, which operates Swedish Hospital, confirmed that no hospital staff or patients were harmed during the attack and stated that the organization was fully cooperating with law enforcement investigators.

Superintendent Snelling and Mayor Brandon Johnson used the tragedy to underscore the inherent dangers of police work. Snelling emphasized that officers knowingly enter dangerous situations every day as part of their duty, calling the profession 'extremely dangerous.' Mayor Johnson expressed gratitude to the Chicago Police Department and pledged continued support, stressing the importance of ensuring officers have adequate resources and services to perform their jobs effectively and safely.

Governor JB Pritzker also addressed the shooting on social media, expressing condolences and calling for mourning across Illinois. The incident has prompted broader questions about security protocols in hospitals, particularly around the supervision of prisoners receiving medical treatment. Alderperson Vasquez indicated that an investigation into potential protocol failures would be pursued to prevent similar tragedies from occurring in the future and to ensure that justice is properly served.

Researchers at Columbia University and the University of Missouri are developing a revolutionary knee implant called NOVAKnee, which uses living biological materials rather than traditional metal and plastic components. The implant is built on a biodegradable scaffold populated with stem-cell-derived bone and cartilage. Once implanted, the scaffold is designed to gradually dissolve as the body replaces it with natural bone and cartilage, ultimately integrating seamlessly into the patient's own skeletal structure.

Conventional knee replacements function well but have a lifespan of only 15 to 20 years, making them best suited for older patients who are unlikely to outlive the implant. Younger patients face a difficult dilemma: enduring years of pain while waiting until the appropriate age for surgery, or accepting an implant early and facing the prospect of painful and complicated revision surgery in the future. NOVAKnee is specifically designed to address this gap and provide younger patients with a more sustainable long-term solution.

Revision surgery — the process of replacing a failed implant — is particularly problematic. Surgeons must carefully extract the original implant without damaging surrounding bone, and a larger incision is required to fit the new device. Older patients undergoing revision face the added complication of reduced bone density, making the procedure riskier. Younger patients receiving a first implant early also face this compounding disadvantage later in life, highlighting the urgent need for an implant that the body can fully absorb and replace.

NOVAKnee has already undergone preliminary testing in lab mice, where miniature versions of the implant were placed beneath the skin to observe the body's biological response. Larger animal trials that replicate actual knee replacement conditions are planned for the near future, though the specific animal model has not yet been disclosed. The research team, supported by the federally funded NITRO project, hopes to commence human clinical trials as early as 2028, pending successful outcomes in the animal studies.

Professors Clark Hung and Nadeen Chahine of Columbia University, two of the lead developers, spoke with Live Science about the technology's potential. The phrase that captures the implant's core concept is 'eventually, it becomes you' — meaning the artificial scaffold disappears and is wholly replaced by the patient's own biological tissue. If human trials succeed, this technology could fundamentally transform the field of orthopedic medicine, offering younger patients with joint disease a genuinely lasting and biologically natural solution.